Although some media have suggested that the experimental cannabis-based painkiller that caused “serious accident” during clinical trials of the drug this week in France, leaving one person brain death and hospitalization of at least five others, the Ministry of Health in the country confirmed that the tragedy It did not result from formulations containing cannabinoids.
On Thursday evening, French media reported the news of a major disaster in the western city of Rennes, where the number of participants in a study of cannabis-based drugs were delivered to the hospital to seek treatment side effects. The report said that the worst injury was brain-dead, at least one person, while the conditions of the other five victims were unknown. Later it was found that all of the victims suffered from a “critical neurological condition.”
While some news organizations ran wild with headlines that imply a drug derived from cannabis plants destroyed brains of a few people, a spokesman for the French Ministry of Health quickly destroy the claim, saying that the drug is responsible has nothing to do with cannabis. The Ministry of Health refused that the drug is actually a complex tested on the same drug was the so-called fatty acid amide hydrolase (FAAH) inhibitor. This class of drugs designed to inhibit the enzyme that degrades natural endocannabinoid that leads to increased levels of endocannabinoid. Many doctors and researchers have expressed interest in using this type of drug use to the medical potential of cannabis without producing psychoactive effects. Previous clinical trials have shown that inhibitors of FAAH safe for humans, but this new situation may close the door on that prospect. At the present time, Yale University is sponsoring another clinical trial for the use of these potentially dangerous FAAH inhibitor for the treatment of “withdrawal of cannabis.”
The fact that we know that a company called Biotrial was behind the incident. This is a research center that has facilities around the world, including one in New Jersey, was hired by an unknown drug company to start Phase I clinical trials of the drug on the mystery. This part of the study involves testing on a small group of healthy participants to assess the safety and tolerability of the drug. Reports show that all of the volunteers were administered the drug orally, since earlier this week.
“The trial was conducted in full compliance with international rules and procedures followed Biotrial at every stage during the trial,” said Biotrial in a statement. “Priority Biotrial is the safety of our actors.”
Paris prosecutors are reported to have begun a full-scale investigation into the incident.
It is still too early to say exactly what happened in this case. I hope that this accident in France will serve as a wake-call for scientists who experiment with the endocannabinoid system in our body in unnatural ways, ignoring the obvious solution, which grows out of the ground beneath them. High Times will continue to monitor the situation and provide updates as they become available.